Today, the AI Health-Tech company, MedBright AI Investments Inc. (Ticker: MBAI.c or MBAIF for US investors) announced the implementation of the Limmi Disease Insights Platform in a university hospital setting, with a focus on improving detection of kidney stone disease recurrence. UC San Diego Health is the first to use the platform.
Full press release: https://www.globenewswire.com/news-release/2024/02/22/2833631/0/en/MedBright-AI-Announces-Limmi-Disease-Insights-Platform-Being-Used-in-University-Hospital-Setting-to-Improve-Detection-of-Kidney-Stone-Disease-Recurrence.html
The Disease Insights Platform employs advanced AI modeling and comprehensive data integration to analyze complex health data, aiming to predict individual risk factors for kidney stone recurrence.
Dr. Roger Sur from UC San Diego School of Medicine highlights the need for personalized risk prediction and the potential of AI in healthcare.
Additionally, the Limmi AI applications are set to be expanded to predict other diseases and broaden its impact on healthcare management in the future.
Overall the launch of the Limmi Disease Insights Platform displays the variety of MBAI's AI Health-Tech Offerings.
MBAI's main offering is MedMatrix, an AI-powered data analytics platform tailored to assess and analyze crucial aspects of healthcare facilities. It can address patient needs, resource matching, revenue cycle management, patient demographics, facility geography, and competition.
MedMatrix collaborates with healthcare professionals, leveraging advanced AI and data analytics to enhance clinic operations and elevate patient outcomes.
Furthermore, it's projected to boost clinic revenue by 10% without imposing additional costs. Despite MedBright AI Investments Inc.'s market capitalization falling below $20 million, it has achieved notable milestones.
Within a span of two months, agreements were secured with 14 clinics across the US and Canada for MedMatrix. Moreover, MedMatrix's capabilities were recently expanded through a partnership with one of MedBright AI Investments Inc.'s clinic groups, underscoring its scalability within the $200 billion addressable market.
More here: https://www.medbright.ai/blog-posts/medbright-ais-medmatrix-to-expand-its-ai-offerings-for-cosmetic-marketing-clinical-trial-analytics
Posted on behalf of Medbright AI Investments Inc.